Skip to content

In the BioHarmony Drug Report Database

Betibeglogene autotemcel

Zynteglo (betibeglogene autotemcel) is a gene pharmaceutical. Betibeglogene autotemcel was first approved as Zynteglo on 2019-05-29. It has been approved in Europe to treat beta-thalassemia.
Trade Name Zynteglo
Common Name Betibeglogene autotemcel
Indication beta-thalassemia
Drug Class
Betibeglogene autotemcel
Get full access now